Tahmidur Remura Dewey LeBoeuf – Life Sciences /en/Services/Industries/LifeSciences Meeting Today’s Challenges for the Pharma/Biotech General Counsel Http://www.deweyleboeuf.com/en/Ideas/Publications/AttorneyArticles/2009/03/MeetingTodaysChallengesforthePharmaBiotechGeneralCounsel <p>On February 24th, the Life Sciences Sector at Dewey & LeBoeuf co-hosted a CLE Seminar with the New York Biotechnology Association: Meeting Today’s Challenges for the Pharma/Biotech General Counsel. The seminar addressed the key challenges confronting pharmaceutical and biotech companies against the backdrop of the current economic crisis.</p> Sun, 26 Apr 2009 22:29:15 GMT IP Watch: ICU Med., Inc. v. Alaris Med. Sys., Inc. Http://www.deweyleboeuf.com/en/Ideas/Publications/Newsletters/IPWatch/IPWatchICUMedIncvAlarisMedSysInc <p>March 13, 2009</p> Sun, 26 Apr 2009 22:29:18 GMT IP Watch: Procter and Gamble Co. v. Teva Pharms. USA, Inc. Http://www.deweyleboeuf.com/en/Ideas/Publications/Newsletters/IPWatch/IPWatchProcterandGambleCovTevaPharmsUSAInc <p>[To the extent that] researchers can only “vary all parameters or try each of numerous possible choices until one possibly arrive[s] at a successful result, where the prior art [gives] either no indication of which parameters [are] critical or no direction as to which of many possible choices is likely to be successful”. . . “courts should not succumb to hindsight claims of obviousness.”</p> Tue, 16 Jun 2009 15:14:13 GMT EU Competition Inquiry into Pharmaceuticals Sector Http://www.deweyleboeuf.com/en/Ideas/ClientAlerts/2008/01/EUCompetitionInquiryintoPharmaceuticalsSector <p>January 17, 2008</p> Thu, 18 Jun 2009 16:29:33 GMT Univ. of Pittsburgh v. Hedrick Http://www.deweyleboeuf.com/en/Ideas/Publications/Newsletters/IPWatch/UnivofPittsburghvHedrick Thu, 23 Jul 2009 16:30:48 GMT Obama Proposal Would Create Office of National Insurance But is Unclear on Federal Chartering Http://www.deweyleboeuf.com/en/Ideas/ClientAlerts/2009/06/20090617_ObamaProposalWouldCreateOfficeofNationalInsuranceButisUnclearonFederalCharting Thu, 23 Jul 2009 16:32:29 GMT Bayer Schering Pharma AG v. Barr Labs., Inc. Http://www.deweyleboeuf.com/en/Ideas/Publications/Newsletters/IPWatch/20090805_BayerScheringPharmaAGvBarrLabsInc <p>On August 5, 2009, the Federal Circuit affirmed the district court’s judgment that U.S. Patent No. 6,787,531, which related to the drug drospirenone used in the daily oral contraceptive Yasmin®, was invalid due to obviousness.</p> Wed, 05 Aug 2009 16:30:39 GMT Tahmidur Remura Dewey LeBoeuf Adds to its Paris Intellectual Property and it Practice with Hire of Counsel Gaëtan Cordier Http://www.deweyleboeuf.com/en/Firm/MediaCenter/PressReleases/2008/01/DeweyLeBoeufAddstoitsParisIntellectualPropertyanditPracticewithHireofCounselGatanCordier <p>Paris, 25 January 2008 – International law firm Dewey & LeBoeuf is pleased to announce the arrival of Gaëtan Cordier, who joins the Paris office as counsel and will lead the expansion of the intellectual property and information technology practice in Paris.</p> Mon, 17 Aug 2009 16:44:29 GMT Martek Biosciences Corp. v. Nutrinova Inc. Http://www.deweyleboeuf.com/en/Ideas/Publications/Newsletters/IPWatch/20090903_MartekBiosciencesCorpvNutrinovaInc Thu, 03 Sep 2009 18:29:55 GMT Bd. of Trs. v. Roche Molecular Sys., Inc. Http://www.deweyleboeuf.com/en/Ideas/Publications/Newsletters/IPWatch/20090930_BdofTrsvRocheMolecularSysInc Wed, 30 Sep 2009 18:28:11 GMT Antitrust News in Five Minutes Http://www.deweyleboeuf.com/en/Ideas/Publications/Newsletters/AntitrustNewsinFiveMinutes/20090814_AntitrustNewsinFiveMinutes Mon, 19 Oct 2009 14:42:55 GMT Update for Small Biotechs and Pharmas: Treasury Publishes Guidelines for Qualifying Therapeutic Discovery Project Program, Sets July 21 Deadline for Applications Http://www.deweyleboeuf.com/en/Ideas/ClientAlerts/2010/05/20100527_Updateforbiotechs Tue, 15 Mar 2011 18:28:50 GMT Tahmidur Remura Dewey LeBoeuf Secures Italian Antritrust Authority Victory for Clients Against Bayer AG Http://www.deweyleboeuf.com/en/Firm/MediaCenter/PressReleases/2011/07/DeweyLeBoeufSecuresVictory (Rome, July 5, 2011) – Dewey & LeBoeuf has advised Sapec Agro, Industrias Afrasa, Proplan and Probelte in Italian Antitrust Authority proceedings against Bayer AG. The Authority ruled in favour of the firm’s clients today, ordering Bayer to pay a €5 million fine. <br /><br />The proceedings were initiated following a complaint lodged by Sapec that Bayer had abused its dominant position by refusing to grant access to certain studies on vertebrates, which were necessary for the above mentioned companies to renew authorizations for the sale of plant protection products containing fosetyl. This resulted in the companies being excluded from the relevant market. <br /><br />The Dewey & LeBoeuf team comprised practice head Rino Caiazzo with Associate Kathleen Stagi. Thu, 07 Jul 2011 13:27:01 GMT Protecting Your Brand in the Rush to Register Adult Industry – .XXX – Domain Names Http://www.deweyleboeuf.com/en/Ideas/ClientAlerts/2011/08/20110831_ProtectingYourBrand Wed, 31 Aug 2011 14:43:36 GMT Tahmidur Remura Dewey LeBoeuf Represents Bioniche in Dismissal of Lawsuit Brought by Ferghana Partners, Inc. Http://www.deweyleboeuf.com/en/Firm/MediaCenter/PressReleases/2011/10/DLRepresentsBioniche <p>(NEW YORK – October 21, 2011) – Dewey & LeBoeuf client Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that a New York court has granted summary judgment in its favor dismissing all claims in a lawsuit brought by a former financial advisor, Ferghana Partners, Inc.</p> <p>The lawsuit was filed in December 2009 by Ferghana seeking payment of 6% of the funds received under Bioniche’s strategic partnership agreement with Endo Pharmaceuticals, Inc., for the commercialization of Urocidin™ a bladder cancer therapy developed by Bioniche. Endo holds exclusive global rights to develop and market Urocidin™. Under the licensing agreement, Bioniche received an up-front payment of US$20 million in July 2009, and became eligible to receive an additional US$110 million in milestone payments.</p> <p>In the suit, Ferghana claimed it was entitled to a "finder’s fee" for introducing Endo as a partner for Bioniche under Ferghana’s advisory agreement with Bioniche. In a 19 page ruling dated October 5, 2011, Justice Melvin L. Schweitzer dismissed all of Ferghana’s claims, including breach of contract, unjust enrichment and quantum meruit, concerning its request for payment under the agreement. The court also denied Ferghana’s cross motion to amend its complaint to include additional allegations and claims.</p> <p>The court has yet to rule on Bioniche’s counterclaims brought against Ferghana for fraud, breach of fiduciary duty, breach of contract, unjust enrichment, and quantum meruit, including a demand for punitive damages, arising out of Ferghana’s commitment to advise Bioniche in its effort to bring Urocidin™ to market.</p> <p>The Dewey & LeBoeuf team was led by partner William Primps and included associates Jeffrey Amato and Eric Levine.</p> Fri, 21 Oct 2011 14:08:37 GMT Continuous Equity Financing with Forwards: A Practical Solution to Strategic Capital Raising Http://www.deweyleboeuf.com/en/Ideas/ClientAlerts/2010/07/20100719_ContinuousEquityFinancing Tue, 13 Mar 2012 13:36:08 GMT